FDA Approves Bayer Drug for Advanced Lung Cancer
Source: www.newswire.com Key Points: Bayer Hyrnuo lung cancer drug was approved by the FDA for HER2-mutated NSCLC after prior treatments. Clinical trials showed tumor shrinkage in up to 71% of patients. FDA also cleared a companion test to identify eligible patients. The U.S. Food and Drug Administration approved Bayer Hyrnuo lung cancer therapy for a specific form of advanced lung cancer on Nov. 19, expanding treatment options for patients whose disease has progressed despite earlier care. Targeted Therapy for HER2-Mutated Cases The agency cleared Bayer’s drug, branded as Hyrnuo, for adults with non-squamous non-small cell lung cancer (NSCLC) that carries mutations affecting the HER2 protein. These mutations must be confirmed through an FDA-approved diagnostic test. HER2 plays a key role in regulating cell growth, and changes in this protein can drive cancer development. Bayer Hyrnuo lung cancer is an oral kinase inhibitor, a class of medicines that blocks protein kinases involved in ...